Content about Tarceva

August 19, 2013

Specialty pharmacy CareMed Pharmaceutical Services has been added to a limited-distribution network for a cancer drug sold by Genentech and Astellas Pharma, the company said.

LAKE SUCCESS, N.Y. — Specialty pharmacy CareMed Pharmaceutical Services has been added to a limited-distribution network for a cancer drug sold by Genentech and Astellas Pharma, the company said.

CareMed said it had been selected to supply the drug, Tarceva (erlotinib). The two drug makers stopped distributing the drug, a once-daily treatment for advanced lung cancer, through retail pharmacies at the beginning of July.

July 24, 2013

Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said.

PITTSBURGH — Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said Wednesday.

Mylan said it had entered an agreement with Pfizer, Genentech and OSI that would allow their suit against Mylan over the drug Tarceva (erlotinib) to be dismissed. All other terms and conditions of the settlement are confidential, and the agreement is subject to Department of Justice and Federal Trade Commission review, Mylan said.

July 2, 2013

A cancer drug made by Genentech and Astellas is no longer available through ordinary retail channels and is now available only through a limited-distribution network.

NEW YORK — A cancer drug made by Genentech and Astellas is no longer available through ordinary retail channels and is now available only through a limited-distribution network.

Cancer-focused specialty pharmacy Onco360 said that effective Monday, the drug Tarceva (erlotinib) would no longer be available through retail pharmacies and that had joined a limited-distribution network that the drug makers had set up for the drug. Tarceva is used for treating advanced non-small cell lung cancer and pancreatic cancer.